Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

26 trials with published results (25%)

Research Maturity

71 completed trials (69% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

2.9%

3 terminated out of 103 trials

Success Rate

95.9%

+9.4% vs benchmark

Late-Stage Pipeline

25%

26 trials in Phase 3/4

Results Transparency

37%

26 of 71 completed with results

Key Signals

26 with results96% success

Data Visualizations

Phase Distribution

73Total
Not Applicable (19)
Early P 1 (1)
P 1 (13)
P 2 (14)
P 3 (23)
P 4 (3)

Trial Status

Completed71
Recruiting14
Unknown7
Not Yet Recruiting4
Terminated3
Withdrawn2

Trial Success Rate

95.9%

Benchmark: 86.5%

Based on 71 completed trials

Clinical Trials (103)

Showing 20 of 20 trials
NCT06383806Not ApplicableRecruitingPrimary

Decreasing Nightmares in Adults With Narcolepsy

NCT05615584Not ApplicableCompletedPrimary

Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence

NCT07613710Phase 1RecruitingPrimary

A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy

NCT07675135Phase 3Recruiting

A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy

NCT05709873Not ApplicableCompletedPrimary

Narcolepsy Nightmare Study

NCT07540364Phase 3Not Yet RecruitingPrimary

A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE)

NCT03881852Phase 2CompletedPrimary

Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)

NCT05536011Recruiting

WAKIX® (Pitolisant) Pregnancy Registry

NCT05371483Enrolling By InvitationPrimary

Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments

NCT06586138CompletedPrimary

Study of Psychological, Sociological and Professional Factors Associated With Maintenance of Wakefulness Test

NCT07625280Phase 3Not Yet RecruitingPrimary

A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH

NCT05773872Not ApplicableRecruitingPrimary

Evaluation of Social Cognition in Patient With Type 1 or Type 2 Narcolepsy Versus Patients With Idiopathic Hypersomnia

NCT05059223Phase 3CompletedPrimary

A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy

NCT00916253Not ApplicableCompletedPrimary

Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies

NCT07493265Phase 2RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

NCT05869773Phase 4CompletedPrimary

A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy

NCT06179407Phase 1TerminatedPrimary

Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

NCT06279247RecruitingPrimary

Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy

NCT06792708CompletedPrimary

Observational Study of LUMRYZ in Narcolepsy

NCT04806620Recruiting

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

Scroll to load more

Research Network

Activity Timeline